Mesoblast Limited
16.98
-0.20 (-1.16%)
At close: Jan 14, 2025, 3:59 PM
15.88
-6.48%
Pre-market Jan 15, 2025, 04:00 AM EST
undefined%
Bid 16.25
Market Cap 1.95B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.81
PE Ratio (ttm) -9.38
Forward PE n/a
Analyst Buy
Ask 16.7
Volume 1,264,014
Avg. Volume (20D) 389,067
Open 16.19
Previous Close 17.18
Day's Range 15.70 - 17.67
52-Week Range 1.61 - 22.00
Beta undefined

About MESO

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchyma...

Industry Biotechnology
Sector Healthcare
IPO Date Jan 20, 2010
Employees 73
Stock Exchange NASDAQ
Ticker Symbol MESO

Analyst Forecast

According to 4 analyst ratings, the average rating for MESO stock is "Buy." The 12-month stock price forecast is $13.5, which is a decrease of -20.49% from the latest price.

Buy 75.00%
Hold 25.00%
Sell 0.00%
Stock Forecasts
3 weeks ago · Source
+36.82%
Mesoblast shares are trading higher after the comp... Unlock content with Pro Subscription
3 months ago · Source
+7.5%
Mesoblast shares are trading higher after the company entered into a convertible note subscription agreement with its largest shareholder.